André Baruchel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
André Baruchel has a total of 661 co-authors. Here are the top co-authors by number of shared publications:
- Susana Rives
Pediatric Cancer Center Barcelona (PCCB), Hospital Sant Joan de Déu de Barcelona, Institut de Recerca Sant Joan de Déu, Leukemia, Barcelona, Spain
12 shared publications - Arnaud Petit
Hôpital Armand Trousseau, APHP Sorbonne Université Paris France
10 shared publications - Jochen Buechner
Department of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo, Norway
10 shared publications - Nicolas Boissel
Hôpital Saint-Louis, AP-HP, Paris, France
9 shared publications Gérard Michel
Hôpital La Timone
7 shared publicationsHeather E. Stefanski
Center for International Blood and Marrow Transplant Research, NMDP, Minneapolis, MN
7 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (31) , 2999-3005
Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL
We report the 5-year analysis of tisagenlecleucel in 79 pediatric and young adult patients with relapsed or refractory (r/r) B-cell ALL (B-ALL) from the global phase II ELIANA trial (ClinicalTrials.gov identifier: NCT02435849 ), with a median follow-up of 79.4 months. Tisagenlecleucel was administered as a single infusion with dosing normalized by weight in patients ≤50 kg. Key long-term end points included relapse-free survival (RFS), overall survival (OS), and safety. Censoring included loss to follow-up, withdrawal of consent, new anticancer therapy (± stem cell transplantation [SCT]), and death. The estimated 5-year RFS among responders (n = 70) with and without inclusion of SCT in censoring for new anticancer therapies was 47.3% and 51.0%, respectively. The median time to B-cell recovery was not reached with censoring for all further anticancer therapies, including SCT. The median OS was not reached. The estimated OS at 5 years was 55.0% and 62.4% with and without inclusion of SCT in censoring for new anticancer therapies, respectively. In total, 17 responders received a postinfusion SCT, 14 while still in complete remission. No new or unexpected adverse events were reported. These findings continue to support the potential of tisagenlecleucel as definitive therapy for many heavily pretreated pediatric and young adult patients with r/r B-ALL.
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (31) , 2999-3005
Open AccessLong-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL
We report the 5-year analysis of tisagenlecleucel in 79 pediatric and young adult patients with relapsed or refractory (r/r) B-cell ALL (B-ALL) from the global phase II ELIANA trial (ClinicalTrials.gov identifier: NCT02435849 ), with a median follow-up of 79.4 months. Tisagenlecleucel was administered as a single infusion with dosing normalized by weight in patients ≤50 kg. Key long-term end points included relapse-free survival (RFS), overall survival (OS), and safety. Censoring included loss to follow-up, withdrawal of consent, new anticancer therapy (± stem cell transplantation [SCT]), and death. The estimated 5-year RFS among responders (n = 70) with and without inclusion of SCT in censoring for new anticancer therapies was 47.3% and 51.0%, respectively. The median time to B-cell recovery was not reached with censoring for all further anticancer therapies, including SCT. The median OS was not reached. The estimated OS at 5 years was 55.0% and 62.4% with and without inclusion of SCT in censoring for new anticancer therapies, respectively. In total, 17 responders received a postinfusion SCT, 14 while still in complete remission. No new or unexpected adverse events were reported. These findings continue to support the potential of tisagenlecleucel as definitive therapy for many heavily pretreated pediatric and young adult patients with r/r B-ALL.
- Open Access
- 31 August 2026
- Published by Springer Nature in Leukemia
- p. 1-10
Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome
This multicenter real-world study identifies critical determinants of outcome for tisagenlecleucel (tisa-cel) in treating post-HSCT relapse in 220 children/young adults with B-ALL from 31 European centers. Median follow-up was 30.0 months, with a 43.6% 2-year event-free survival (EFS), 67.2% overall-survival (OS), and 57.1% incidence of CAR-T failure. CAR-T for relapse after transplant from a matched sibling donor (MSD) compared to alternative donors was associated with lower 2-year-OS (MSD 59.1%, mismatched donor MMD 80.2%, matched family/unrelated donor MFD/MUD 68.3%, p = 0.046). Two-year incidence of CAR-T failure was highest for MSD (MSD 73.8%, MFD/MUD 49.7%, MMD 52.2%, p = 0.006). Patients who had relapsed early (< 6 months post HSCT) showed inferior 2-year-EFS (23.7%) and OS (47.2%) compared to patients with late relapse, ≥ 6 months after HSCT (EFS 49.8%, p = 0.001; OS 73.9%, p < 0.001). Early relapse was associated with a higher incidence of CAR-T failure and relapse after tisa-cel, particularly CD19+ relapses. Outcomes correlated with disease burden at lymphodepletion: 2-year-OS was 81.7% for MRD–, 69.2% for MRD+, and 55.2% for patients in non-remission ( p = 0.003), with incidence of CAR-T failure highest in non-remission. Prior transplant from an MSD, early post-HSCT relapse, and disease burden at lymphodepletion identify patients at increased risk of CAR-T failure after HSCT.
- 31 August 2026
- Published by Springer Nature in Leukemia
- p. 1-10
Open AccessTisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome
This multicenter real-world study identifies critical determinants of outcome for tisagenlecleucel (tisa-cel) in treating post-HSCT relapse in 220 children/young adults with B-ALL from 31 European centers. Median follow-up was 30.0 months, with a 43.6% 2-year event-free survival (EFS), 67.2% overall-survival (OS), and 57.1% incidence of CAR-T failure. CAR-T for relapse after transplant from a matched sibling donor (MSD) compared to alternative donors was associated with lower 2-year-OS (MSD 59.1%, mismatched donor MMD 80.2%, matched family/unrelated donor MFD/MUD 68.3%, p = 0.046). Two-year incidence of CAR-T failure was highest for MSD (MSD 73.8%, MFD/MUD 49.7%, MMD 52.2%, p = 0.006). Patients who had relapsed early (< 6 months post HSCT) showed inferior 2-year-EFS (23.7%) and OS (47.2%) compared to patients with late relapse, ≥ 6 months after HSCT (EFS 49.8%, p = 0.001; OS 73.9%, p < 0.001). Early relapse was associated with a higher incidence of CAR-T failure and relapse after tisa-cel, particularly CD19+ relapses. Outcomes correlated with disease burden at lymphodepletion: 2-year-OS was 81.7% for MRD–, 69.2% for MRD+, and 55.2% for patients in non-remission ( p = 0.003), with incidence of CAR-T failure highest in non-remission. Prior transplant from an MSD, early post-HSCT relapse, and disease burden at lymphodepletion identify patients at increased risk of CAR-T failure after HSCT.
- 20 August 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (11) , 1504-1511
Long-term complications after total body irradiation in children younger than 4 years transplanted for acute lymphoblastic leukemia
Total body irradiation (TBI)-based conditioning is the standard regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in high-risk or relapsed pediatric acute lymphoblastic leukemia (ALL), but is variably used before age 4 because of concerns about long-term toxicity. Long-term physical, educational, and quality-of-life outcomes were assessed in patients from the French long-term follow-up program LEA who underwent TBI-based HSCT for ALL at 2 to n = 37) and compared with those of matched prepubertal older children transplanted at ≥4 years (older group, n = 105). After a mean follow-up of 15.6 years, the number of complications was similar in the two groups (3.3 vs 3.2, p = 0.90). Among the 20 complications analyzed, pulmonary dysfunction was the only event that differed significantly, being more frequent in the older group (43% vs 19%, p = 0.01). In a multivariate multistate model, age group was not associated with a higher risk of transition to a greater complication burden (HR 1.05, 95% CI 0.83–1.32; p = 0.70). Educational outcomes and quality of life were also comparable. These findings do not suggest greater long-term toxicity in children undergoing TBI-based HSCT at 2 to <4 years of age and support reconsideration of the lower age limit for its use.
- 20 August 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (11) , 1504-1511
Long-term complications after total body irradiation in children younger than 4 years transplanted for acute lymphoblastic leukemia
Total body irradiation (TBI)-based conditioning is the standard regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in high-risk or relapsed pediatric acute lymphoblastic leukemia (ALL), but is variably used before age 4 because of concerns about long-term toxicity. Long-term physical, educational, and quality-of-life outcomes were assessed in patients from the French long-term follow-up program LEA who underwent TBI-based HSCT for ALL at 2 to n = 37) and compared with those of matched prepubertal older children transplanted at ≥4 years (older group, n = 105). After a mean follow-up of 15.6 years, the number of complications was similar in the two groups (3.3 vs 3.2, p = 0.90). Among the 20 complications analyzed, pulmonary dysfunction was the only event that differed significantly, being more frequent in the older group (43% vs 19%, p = 0.01). In a multivariate multistate model, age group was not associated with a higher risk of transition to a greater complication burden (HR 1.05, 95% CI 0.83–1.32; p = 0.70). Educational outcomes and quality of life were also comparable. These findings do not suggest greater long-term toxicity in children undergoing TBI-based HSCT at 2 to <4 years of age and support reconsideration of the lower age limit for its use.
- Open Access
- 6 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1856-1865
Identification of predictive factors for reversal of cerebral vasculopathy in an original longitudinal cohort study in newborns with sickle cell anaemia
Summary: Cerebral macrovasculopathy (CV) is a major complication in children with sickle cell anaemia (SCA) and usually requires a long‐term transfusion programme (TP) to prevent stroke. This study aimed to identify factors predicting reversal of CV on TP in a single‐centre newborn cohort. Among 375 patients, 50 presented CV and received TP. Median age at diagnosis was 4.9 years [3.6–6.1], with median follow‐up of 13.3 years (915 patient‐years). Transcranial Doppler (TCD) velocities and magnetic resonance angiography (MRA) normalised in 35 patients, that is, they had reversal of CV (RCV group). Fifteen patients had no reversal of CV (No‐RCV group). Kaplan–Meier analysis estimated that 48% (95% confidence interval [CI] [33–62]) still had abnormal TCD and/or MRA 5 years after diagnosis. In a multivariate Cox model, three baseline factors independently predicted CV reversal: age at CV onset, initial severity of stenosis and bronchial obstruction. Older age at diagnosis increased the likelihood of CV reversal (hazard ratio [HR] 1.31 per year, 95% CI [1.08–1.59], p = 0.01). In contrast, severe stenosis (HR 0.72 per 10% increase, 95% CI [0.62–0.85], p < 0.0001) and bronchial obstruction (HR 0.14, 95% CI [0.03–0.63], p = 0.001) reduced the likelihood of CV reversal. These results suggest that, beyond TP, managing bronchial obstruction may improve vascular outcomes.
- 6 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1856-1865
Open AccessIdentification of predictive factors for reversal of cerebral vasculopathy in an original longitudinal cohort study in newborns with sickle cell anaemia
Summary: Cerebral macrovasculopathy (CV) is a major complication in children with sickle cell anaemia (SCA) and usually requires a long‐term transfusion programme (TP) to prevent stroke. This study aimed to identify factors predicting reversal of CV on TP in a single‐centre newborn cohort. Among 375 patients, 50 presented CV and received TP. Median age at diagnosis was 4.9 years [3.6–6.1], with median follow‐up of 13.3 years (915 patient‐years). Transcranial Doppler (TCD) velocities and magnetic resonance angiography (MRA) normalised in 35 patients, that is, they had reversal of CV (RCV group). Fifteen patients had no reversal of CV (No‐RCV group). Kaplan–Meier analysis estimated that 48% (95% confidence interval [CI] [33–62]) still had abnormal TCD and/or MRA 5 years after diagnosis. In a multivariate Cox model, three baseline factors independently predicted CV reversal: age at CV onset, initial severity of stenosis and bronchial obstruction. Older age at diagnosis increased the likelihood of CV reversal (hazard ratio [HR] 1.31 per year, 95% CI [1.08–1.59], p = 0.01). In contrast, severe stenosis (HR 0.72 per 10% increase, 95% CI [0.62–0.85], p < 0.0001) and bronchial obstruction (HR 0.14, 95% CI [0.03–0.63], p = 0.001) reduced the likelihood of CV reversal. These results suggest that, beyond TP, managing bronchial obstruction may improve vascular outcomes.
- Open Access
- 20 May 2026
- Published by Springer Nature in Research Square
Long-Term Complications After Total Body Irradiation in Children Younger Than 4 Years Transplanted for Acute Lymphoblastic Leukemia
Total body irradiation (TBI)-based conditioning is the standard regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in high-risk or relapsed pediatric acute lymphoblastic leukemia (ALL) but is variably used before age 4 because of concerns about long-term toxicity. Long-term physical, educational, and quality-of-life outcomes were assessed in patients from the French long-term follow-up program LEA who underwent TBI-based HSCT for ALL at 2 to <4 years of age (younger group, n=37) and compared with those of matched older prepubertal children transplanted at ≥4 years (older group, n=105). After a mean follow-up of 15.6 years, the number of long-term complications was similar in the two groups (3.3 versus 3.2, p=0.90). Among the 20 complications analyzed, pulmonary dysfunction was the only event that differed significantly, being more frequent in the older group (43% versus 19%, p=0.01). In a multivariate multistate model, age group was not associated with a higher risk of transition to a greater complication burden (HR 1.05, 95% CI 0.83-1.32; p=0.70). Educational outcomes and quality of life were comparable between groups. These findings do not suggest greater long-term toxicity in children undergoing TBI-based HSCT before 4 years of age and support reconsideration of the lower age limit for its use.
- 20 May 2026
- Published by Springer Nature in Research Square
Open AccessLong-Term Complications After Total Body Irradiation in Children Younger Than 4 Years Transplanted for Acute Lymphoblastic Leukemia
Total body irradiation (TBI)-based conditioning is the standard regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in high-risk or relapsed pediatric acute lymphoblastic leukemia (ALL) but is variably used before age 4 because of concerns about long-term toxicity. Long-term physical, educational, and quality-of-life outcomes were assessed in patients from the French long-term follow-up program LEA who underwent TBI-based HSCT for ALL at 2 to <4 years of age (younger group, n=37) and compared with those of matched older prepubertal children transplanted at ≥4 years (older group, n=105). After a mean follow-up of 15.6 years, the number of long-term complications was similar in the two groups (3.3 versus 3.2, p=0.90). Among the 20 complications analyzed, pulmonary dysfunction was the only event that differed significantly, being more frequent in the older group (43% versus 19%, p=0.01). In a multivariate multistate model, age group was not associated with a higher risk of transition to a greater complication burden (HR 1.05, 95% CI 0.83-1.32; p=0.70). Educational outcomes and quality of life were comparable between groups. These findings do not suggest greater long-term toxicity in children undergoing TBI-based HSCT before 4 years of age and support reconsideration of the lower age limit for its use.
- Open Access
- 21 April 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (6) , 1261-1270
Genomic fusion breakpoints for DNA-based measurable residual disease monitoring in pediatric acute lymphoblastic leukemia
Measurable residual disease (MRD) is a key prognostic factor in pediatric acute lymphoblastic leukemia (ALL), but current gold-standard methods based on immunoglobulin/T-cell receptor (IG/TCR) rearrangements are complex and not informative in a subset of patients. Genomic breakpoints of oncogenic fusions (GFBs) are stable, biologically grounded markers that may overcome these limitations and improve MRD assessment. In a cohort of 403 patients with known or suspected fusions, a short-read, capture-based next-generation sequencing strategy coupled with an open-source pipeline identified patient-specific GFBs in 97% of cases. GFB-based MRD assays implemented by qPCR or ddPCR showed very high specificity and allowed lower detection thresholds, resulting in improved sensitivity relative to IG/TCR-based assays. Longitudinal monitoring in 104 patients across multiple pediatric ALL fusion subtypes demonstrated excellent overall concordance between methods in non-BCR::ABL ALL, while revealing fusion-dependent differences. GFB-based MRD was particularly informative in ETV6::RUNX1- and MEF2D-rearranged ALL, where IG/TCR tracking is frequently suboptimal or unreliable due to ongoing rearrangements or the absence of VDJ recombination, respectively. Altogether, this large-scale study establishes GFBs as robust, clinically implementable MRD markers and supports their integration into clinical strategies, provided that subtype-specific biology is considered when selecting markers and interpreting results. The alternative text for this image may have been generated using AI.
- 21 April 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (6) , 1261-1270
Open AccessGenomic fusion breakpoints for DNA-based measurable residual disease monitoring in pediatric acute lymphoblastic leukemia
Measurable residual disease (MRD) is a key prognostic factor in pediatric acute lymphoblastic leukemia (ALL), but current gold-standard methods based on immunoglobulin/T-cell receptor (IG/TCR) rearrangements are complex and not informative in a subset of patients. Genomic breakpoints of oncogenic fusions (GFBs) are stable, biologically grounded markers that may overcome these limitations and improve MRD assessment. In a cohort of 403 patients with known or suspected fusions, a short-read, capture-based next-generation sequencing strategy coupled with an open-source pipeline identified patient-specific GFBs in 97% of cases. GFB-based MRD assays implemented by qPCR or ddPCR showed very high specificity and allowed lower detection thresholds, resulting in improved sensitivity relative to IG/TCR-based assays. Longitudinal monitoring in 104 patients across multiple pediatric ALL fusion subtypes demonstrated excellent overall concordance between methods in non-BCR::ABL ALL, while revealing fusion-dependent differences. GFB-based MRD was particularly informative in ETV6::RUNX1- and MEF2D-rearranged ALL, where IG/TCR tracking is frequently suboptimal or unreliable due to ongoing rearrangements or the absence of VDJ recombination, respectively. Altogether, this large-scale study establishes GFBs as robust, clinically implementable MRD markers and supports their integration into clinical strategies, provided that subtype-specific biology is considered when selecting markers and interpreting results. The alternative text for this image may have been generated using AI.
- 24 February 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (5) , 1027-1034
Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia
Tisagenlecleucel (tisa-cel), an autologous anti-CD19 CAR T-cell therapy, has significantly improved outcomes in pediatric, adolescents and young adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R BCP-ALL). However, 30–50% experience early failure or relapse. We retrospectively analyzed 52 cases of early failures (n = 13) or relapses (n = 39), evaluating post-tisa-cel outcomes and prognostic factors. CD19 antigen loss was the only factor associated with a lower complete remission rate after salvage therapy (OR = 0.16, 95%CI [0.03–0.90], p = 0.04). Median overall survival (OS) was 14.5 months, with a 2-year OS of 37.4% (95%CI [24.4–50.4]), similar between early failure (38.5%) and relapse (37.0%) groups (p = 0.78). Patients with measurable residual disease only at salvage initiation had significantly improved 2-year OS (61.9%, (95%CI [38.1–78.8])) compared to those with overt disease (20.7%, (95%CI [8.4–36.7], p = 0.008)). Factors associated with inferior OS included high pre-infusion tumor burden (HR = 3.57, p < 0.01), and prior inotuzumab ozogamicin exposure (HR = 3.81, p < 0.01). Although salvage therapies and hematopoietic stem cell transplantation benefit some patients, 5 of 18 transplanted patients died from treatment-related toxicity, underscoring the significant associated risks. These findings highlight the poor prognosis of tisa-cel failures and the urgent need for novel strategies.
- 24 February 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (5) , 1027-1034
Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia
Tisagenlecleucel (tisa-cel), an autologous anti-CD19 CAR T-cell therapy, has significantly improved outcomes in pediatric, adolescents and young adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R BCP-ALL). However, 30–50% experience early failure or relapse. We retrospectively analyzed 52 cases of early failures (n = 13) or relapses (n = 39), evaluating post-tisa-cel outcomes and prognostic factors. CD19 antigen loss was the only factor associated with a lower complete remission rate after salvage therapy (OR = 0.16, 95%CI [0.03–0.90], p = 0.04). Median overall survival (OS) was 14.5 months, with a 2-year OS of 37.4% (95%CI [24.4–50.4]), similar between early failure (38.5%) and relapse (37.0%) groups (p = 0.78). Patients with measurable residual disease only at salvage initiation had significantly improved 2-year OS (61.9%, (95%CI [38.1–78.8])) compared to those with overt disease (20.7%, (95%CI [8.4–36.7], p = 0.008)). Factors associated with inferior OS included high pre-infusion tumor burden (HR = 3.57, p < 0.01), and prior inotuzumab ozogamicin exposure (HR = 3.81, p < 0.01). Although salvage therapies and hematopoietic stem cell transplantation benefit some patients, 5 of 18 transplanted patients died from treatment-related toxicity, underscoring the significant associated risks. These findings highlight the poor prognosis of tisa-cel failures and the urgent need for novel strategies.
- Open Access
Targeting glucocorticoid-induced CD20 activation in preclinical models of B-ALL
Pediatric B-cell acute lymphoblastic leukemia (B-ALL) is effectively controlled with contemporary multi-agent chemotherapy, resulting to 5-year survival rates above 90%. However, relapse occurs in 15-20% of patients due to minimal residual disease (MRD), characterized by the presence of persisting and resistant leukemic cells, and associated with a poor clinical outcome. Despite its prognostic relevance, the molecular features driving MRD are poorly characterized. In this study, we developed patient-derived xenograft (PDX) models from matched diagnosis and relapse B-ALL samples combined to chemotherapy to mimic MRD in vivo . Drug-tolerant leukemic cells were profiled using single-cell RNA sequencing and we identified a transcriptionally distinct MRD-like population enriched for cell-quiescence, inflammatory stress, and B-cell receptor pathway signatures. Strikingly, the B-lymphocyte surface antigen CD20, encoding by MS4A1 gene, emerged as a consistent upregulated marker in MRD cells from PDXs and patients with diverse oncogenic subtypes. We further demonstrated that CD20 expression is induced by glucocorticoid exposure, creating a therapeutic opportunity where anti-CD20 monoclonal antibodies selectively eradicated MRD cells in vivo . Our data highlight CD20 not only as a biomarker but as an actionable vulnerability in B-ALL MRD, supporting clinical evaluation of anti-CD20 immunotherapy during induction treatment to kill drug-resistant cells and reduce relapse risk.
Open AccessTargeting glucocorticoid-induced CD20 activation in preclinical models of B-ALL
Pediatric B-cell acute lymphoblastic leukemia (B-ALL) is effectively controlled with contemporary multi-agent chemotherapy, resulting to 5-year survival rates above 90%. However, relapse occurs in 15-20% of patients due to minimal residual disease (MRD), characterized by the presence of persisting and resistant leukemic cells, and associated with a poor clinical outcome. Despite its prognostic relevance, the molecular features driving MRD are poorly characterized. In this study, we developed patient-derived xenograft (PDX) models from matched diagnosis and relapse B-ALL samples combined to chemotherapy to mimic MRD in vivo . Drug-tolerant leukemic cells were profiled using single-cell RNA sequencing and we identified a transcriptionally distinct MRD-like population enriched for cell-quiescence, inflammatory stress, and B-cell receptor pathway signatures. Strikingly, the B-lymphocyte surface antigen CD20, encoding by MS4A1 gene, emerged as a consistent upregulated marker in MRD cells from PDXs and patients with diverse oncogenic subtypes. We further demonstrated that CD20 expression is induced by glucocorticoid exposure, creating a therapeutic opportunity where anti-CD20 monoclonal antibodies selectively eradicated MRD cells in vivo . Our data highlight CD20 not only as a biomarker but as an actionable vulnerability in B-ALL MRD, supporting clinical evaluation of anti-CD20 immunotherapy during induction treatment to kill drug-resistant cells and reduce relapse risk.
- Open Access
- 3 December 2025
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 95 (1) , 116
Selection of isatuximab dosing regimen in pediatric patients with leukemia using population pharmacokinetics
Purpose Isatuximab, an immunoglobulin G monoclonal antibody that targets a specific CD38 epitope, is approved in combination with dexamethasone plus either pomalidomide or carfilzomib for treatment of adults with relapsed or refractory (R/R) multiple myeloma. Isatuximab demonstrated significant anti-leukemic activity in preclinical models. In the phase 2 ISAKIDS study (NCT03860844), isatuximab was tested as combination therapy for pediatric patients with R/R acute lymphoblastic leukemia and acute myeloid leukemia. Here, we use population pharmacokinetics (PopPK) to select the appropriate isatuximab dose for infants aged 1–24 months in ISAKIDS. Methods An initial PK modeling and simulation strategy was applied to the first 18 tested patients to confirm the isatuximab 20-mg/kg dose administered to patients aged 24 months or older and to explore the dose needed for the youngest patients. The PK of isatuximab in children was characterized by pooling data from ISAKIDS with adult data from the phase 2 ISLAY study (NCT02999633). Results The PopPK model predicted a slight drug underexposure (median decrease of about 30%) in pediatric patients aged 10–24 months (9–12 kg) compared with reference adults (51–100 kg), which did not require a dose adjustment, as no isatuximab exposure versus efficacy relationships were observed in these clinical settings. Conclusion The modeling and simulation strategies in this study support the previous selection of a 20-mg/kg dose for all age groups and enabled both de-risking of dose selection and the ability to pursue additional pediatric investigation of isatuximab in the youngest age group of patients with acute leukemias.
- 3 December 2025
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 95 (1) , 116
Open AccessSelection of isatuximab dosing regimen in pediatric patients with leukemia using population pharmacokinetics
Purpose Isatuximab, an immunoglobulin G monoclonal antibody that targets a specific CD38 epitope, is approved in combination with dexamethasone plus either pomalidomide or carfilzomib for treatment of adults with relapsed or refractory (R/R) multiple myeloma. Isatuximab demonstrated significant anti-leukemic activity in preclinical models. In the phase 2 ISAKIDS study (NCT03860844), isatuximab was tested as combination therapy for pediatric patients with R/R acute lymphoblastic leukemia and acute myeloid leukemia. Here, we use population pharmacokinetics (PopPK) to select the appropriate isatuximab dose for infants aged 1–24 months in ISAKIDS. Methods An initial PK modeling and simulation strategy was applied to the first 18 tested patients to confirm the isatuximab 20-mg/kg dose administered to patients aged 24 months or older and to explore the dose needed for the youngest patients. The PK of isatuximab in children was characterized by pooling data from ISAKIDS with adult data from the phase 2 ISLAY study (NCT02999633). Results The PopPK model predicted a slight drug underexposure (median decrease of about 30%) in pediatric patients aged 10–24 months (9–12 kg) compared with reference adults (51–100 kg), which did not require a dose adjustment, as no isatuximab exposure versus efficacy relationships were observed in these clinical settings. Conclusion The modeling and simulation strategies in this study support the previous selection of a 20-mg/kg dose for all age groups and enabled both de-risking of dose selection and the ability to pursue additional pediatric investigation of isatuximab in the youngest age group of patients with acute leukemias.
- Open Access
- 30 October 2025
- Published by Wiley in HemaSphere
- Vol. 9 (10) , e70245
Isatuximab in combination with chemotherapy for pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia: The ISAKIDS study
Children with relapsed acute leukemia have a poor prognosis; current relapse treatments are toxic, and novel treatments are needed. The anti‐CD38 antibody isatuximab is approved for relapsed‐refractory multiple myeloma in adults. We present results of the ISAKIDS study (NCT03860844) investigating isatuximab in children with relapsed‐refractory acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). This Phase 2, single‐arm, multicenter, open‐label study enrolled children aged 28 days to −4 sensitivity threshold for ALL and 10 −3 sensitivity threshold for AML. One event of fatal cytokine release syndrome was reported in a patient with a high baseline white blood cell count, leading to trial adaptation. The toxicity of isatuximab with chemotherapy was otherwise manageable. Despite initial evidence of efficacy of isatuximab combined with intensive chemotherapy, CR/CRi rates did not meet stringent prespecified criteria to proceed to ISAKIDS Stage 2 (≥60% [T‐ALL] and ≥70% [B‐ALL and AML]).
- 30 October 2025
- Published by Wiley in HemaSphere
- Vol. 9 (10) , e70245
Open AccessIsatuximab in combination with chemotherapy for pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia: The ISAKIDS study
Children with relapsed acute leukemia have a poor prognosis; current relapse treatments are toxic, and novel treatments are needed. The anti‐CD38 antibody isatuximab is approved for relapsed‐refractory multiple myeloma in adults. We present results of the ISAKIDS study (NCT03860844) investigating isatuximab in children with relapsed‐refractory acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). This Phase 2, single‐arm, multicenter, open‐label study enrolled children aged 28 days to −4 sensitivity threshold for ALL and 10 −3 sensitivity threshold for AML. One event of fatal cytokine release syndrome was reported in a patient with a high baseline white blood cell count, leading to trial adaptation. The toxicity of isatuximab with chemotherapy was otherwise manageable. Despite initial evidence of efficacy of isatuximab combined with intensive chemotherapy, CR/CRi rates did not meet stringent prespecified criteria to proceed to ISAKIDS Stage 2 (≥60% [T‐ALL] and ≥70% [B‐ALL and AML]).